COVID-19-associated Miller-Fischer syndrome

WikiDoc Resources for COVID-19-associated Miller-Fischer syndrome
Articles
Most recent articles on COVID-19-associated Miller-Fischer syndrome Most cited articles on COVID-19-associated Miller-Fischer syndrome Review articles on COVID-19-associated Miller-Fischer syndrome Articles on COVID-19-associated Miller-Fischer syndrome in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on COVID-19-associated Miller-Fischer syndrome Images of COVID-19-associated Miller-Fischer syndrome Photos of COVID-19-associated Miller-Fischer syndrome Podcasts & MP3s on COVID-19-associated Miller-Fischer syndrome Videos on COVID-19-associated Miller-Fischer syndrome
Evidence Based Medicine
Cochrane Collaboration on COVID-19-associated Miller-Fischer syndrome Bandolier on COVID-19-associated Miller-Fischer syndrome TRIP on COVID-19-associated Miller-Fischer syndrome
Clinical Trials
Ongoing Trials on COVID-19-associated Miller-Fischer syndrome at Clinical Trials.gov Trial results on COVID-19-associated Miller-Fischer syndrome Clinical Trials on COVID-19-associated Miller-Fischer syndrome at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on COVID-19-associated Miller-Fischer syndrome NICE Guidance on COVID-19-associated Miller-Fischer syndrome NHS PRODIGY Guidance FDA on COVID-19-associated Miller-Fischer syndrome CDC on COVID-19-associated Miller-Fischer syndrome
Books
Books on COVID-19-associated Miller-Fischer syndrome
News
COVID-19-associated Miller-Fischer syndrome in the news Be alerted to news on COVID-19-associated Miller-Fischer syndrome News trends on COVID-19-associated Miller-Fischer syndrome
Commentary
Blogs on COVID-19-associated Miller-Fischer syndrome
Definitions
Definitions of COVID-19-associated Miller-Fischer syndrome
Patient Resources / Community
Patient resources on COVID-19-associated Miller-Fischer syndrome Discussion groups on COVID-19-associated Miller-Fischer syndrome Patient Handouts on COVID-19-associated Miller-Fischer syndrome Directions to Hospitals Treating COVID-19-associated Miller-Fischer syndrome Risk calculators and risk factors for COVID-19-associated Miller-Fischer syndrome
Healthcare Provider Resources
Symptoms of COVID-19-associated Miller-Fischer syndrome Causes & Risk Factors for COVID-19-associated Miller-Fischer syndrome Diagnostic studies for COVID-19-associated Miller-Fischer syndrome Treatment of COVID-19-associated Miller-Fischer syndrome
Continuing Medical Education (CME)
CME Programs on COVID-19-associated Miller-Fischer syndrome
International
COVID-19-associated Miller-Fischer syndrome en Espanol COVID-19-associated Miller-Fischer syndrome en Francais
Business
COVID-19-associated Miller-Fischer syndrome in the Marketplace Patents on COVID-19-associated Miller-Fischer syndrome
Experimental / Informatics
List of terms related to COVID-19-associated Miller-Fischer syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Synonyms and keywords:

Overview

Miller Fisher Syndrome (MFS) is an acute peripheral neuropathy which can develop after exposure to a viral or bacterial infection. It includes triad of ophtalmoplegia, areflexia and ataxia. In covid-19 pandemic period, while covid-19 typically presents with fever, SOB and respiratory symptoms, MFS with prior history of covid-19 has been seen in several cases all around the world.
One retrospective study in 214 patients has shown that 8.9 % of covid-19 patients have reported peripheral neurological symptoms.

Historical Perspective

The first reported case of MFS with history of covid-19 was detected on January 2020 in Shanghai, who was a middle-age woman diagnosed with MFS presented with areflexia, acute weakness in both legs and severe fatigue. Further reports were announced by medical groups in Spain and the USA which presented neuro-ophtalmological symptoms.

Classification

MFS is a rare variant of Guillain-Barre syndrome, characterized by ophtalmoplegia, areflexia and ataxia.

Pathophysiology

MFS is related to dysfunction of third, forth and sixth cranial nerves. A typical serological finding in patients with MFS and prior history of covid-19 is antibodies against GQ1b ganglioside, though negative test for antibodies does not rule out the diagnosis. The presence of ophtalmoparesis in MFS is related to a action of anti-GQ1b antibodies on the neuromuscular junction between the cranial nerves and ocular muscle. ELISA test is positive in 70% to 90% of patients.

Causes

Although MFS has been detected in some patients with covid-19, other viral and bacterial infections can also cause MFS

• Influenza virus
• Cytomegalovirus
• Zika virus
• Mycoplasma
• Campylobacter

Differentiating COVID-19-associated Miller-Fischer syndrome from other Diseases

MFS must be differentiated from other diseases that cause ophthalmoplegia, areflexia, and ataxia, such as myasthenia gravis, botulism, diphtheria, brain stem stroke, brain stem encephalitis and basal meningitis. It is essential to rule out emergent neurological disorders like stroke or brain injury in patients with MFS symptoms.

Epidemiology and Demographics

While the incidence of MFS is one or two person per million each year, the prevalence of MFS associated with covid-19 is still unknown.

Risk Factors

There are no established risk factors for [disease name].

OR

The most potent risk factor in the development of [disease name] is [risk factor 1]. Other risk factors include [risk factor 2], [risk factor 3], and [risk factor 4].

OR

Common risk factors in the development of [disease name] include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

OR

Common risk factors in the development of [disease name] may be occupational, environmental, genetic, and viral.

Screening

There is insufficient evidence to recommend routine screening for [disease/malignancy].

OR

According to the [guideline name], screening for [disease name] is not recommended.

OR

According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].

Natural History, Complications, and Prognosis

If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].

OR

Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].

OR

Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.

Diagnosis

Diagnostic Study of Choice

The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].

OR

The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].

OR

The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].

OR

There are no established criteria for the diagnosis of [disease name].

History and Symptoms

The majority of patients with [disease name] are asymptomatic.

OR

The hallmark of [disease name] is [finding]. A positive history of [finding 1] and [finding 2] is suggestive of [disease name]. The most common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3]. Common symptoms of [disease] include [symptom 1], [symptom 2], and [symptom 3]. Less common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3].

Physical Examination

Patients with [disease name] usually appear [general appearance]. Physical examination of patients with [disease name] is usually remarkable for [finding 1], [finding 2], and [finding 3].

OR

Common physical examination findings of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

The presence of [finding(s)] on physical examination is diagnostic of [disease name].

OR

The presence of [finding(s)] on physical examination is highly suggestive of [disease name].

Laboratory Findings

An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].

OR

Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

OR

[Test] is usually normal among patients with [disease name].

OR

Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].

OR

There are no diagnostic laboratory findings associated with [disease name].

Electrocardiogram

There are no ECG findings associated with [disease name].

OR

An ECG may be helpful in the diagnosis of [disease name]. Findings on an ECG suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

X-ray

There are no x-ray findings associated with [disease name].

OR

An x-ray may be helpful in the diagnosis of [disease name]. Findings on an x-ray suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no x-ray findings associated with [disease name]. However, an x-ray may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

Echocardiography or Ultrasound

There are no echocardiography/ultrasound findings associated with [disease name].

OR

Echocardiography/ultrasound may be helpful in the diagnosis of [disease name]. Findings on an echocardiography/ultrasound suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no echocardiography/ultrasound findings associated with [disease name]. However, an echocardiography/ultrasound may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

CT scan

There are no CT scan findings associated with [disease name].

OR

[Location] CT scan may be helpful in the diagnosis of [disease name]. Findings on CT scan suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no CT scan findings associated with [disease name]. However, a CT scan may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

MRI

There are no MRI findings associated with [disease name].

OR

[Location] MRI may be helpful in the diagnosis of [disease name]. Findings on MRI suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no MRI findings associated with [disease name]. However, a MRI may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

Other Imaging Findings

There are no other imaging findings associated with [disease name].

OR

[Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

There are no other diagnostic studies associated with [disease name].

OR

[Diagnostic study] may be helpful in the diagnosis of [disease name]. Findings suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

Other diagnostic studies for [disease name] include [diagnostic study 1], which demonstrates [finding 1], [finding 2], and [finding 3], and [diagnostic study 2], which demonstrates [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

OR

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

OR

The majority of cases of [disease name] are self-limited and require only supportive care.

OR

[Disease name] is a medical emergency and requires prompt treatment.

OR

The mainstay of treatment for [disease name] is [therapy].

OR

The optimal therapy for [malignancy name] depends on the stage at diagnosis.

OR

[Therapy] is recommended among all patients who develop [disease name].

OR

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

OR

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

OR

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

OR

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Surgery

Surgical intervention is not recommended for the management of [disease name].

OR

Surgery is not the first-line treatment option for patients with [disease name]. Surgery is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]

OR

The mainstay of treatment for [disease name] is medical therapy. Surgery is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].

OR

The feasibility of surgery depends on the stage of [malignancy] at diagnosis.

OR

Surgery is the mainstay of treatment for [disease or malignancy].

Primary Prevention

There are no established measures for the primary prevention of [disease name].

OR

There are no available vaccines against [disease name].

OR

Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

OR

[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].

Secondary Prevention

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

References

Template:WikiDoc Sources